Truist raised the agency’s value goal on Alnylam (ALNY) to $535 from $459 and retains a Purchase score on the shares forward of its Q3 outcomes. The agency has elevated its Q3 Amvuttra gross sales estimate to $690M and in addition revised its ahead estimates greater to mirror carry by means of from the robust early adoption and extra fast adoption as a primary line agent than beforehand anticipated based mostly on suggestions from prescribers within the quarter who indicated extracardiac manifestations of ATTR-CM are extra widespread than beforehand appreciated, the analyst tells traders in a analysis notice.
-
Make the most of TipRanks Premium at 50% off! Unlock highly effective investing instruments, superior knowledge, and skilled analyst insights that will help you make investments with confidence.
Printed first on TheFly – the final word supply for real-time, market-moving breaking monetary information. Strive Now>>
See the highest shares really useful by analysts >>
Learn Extra on ALNY:
